Breast Cancer

Glioblastoma treatment with surgical resection may benefit patients with worst prognoses.

Undertreated side effects in treatment of some colon and stomach cancers need to be addressed.

Combination therapy with AKT inhibitors shows promise.

Test projects which agent will work best against particular tumors.

Treatment advances have caused significant progress in survivorship.

Top stories of the week on Specialty Pharmacy Times from May 18 to May 22.

New approach seeks to lessen resistance to cancer drugs while mitigating adverse events.

Black men more likely to be diagnosed with breast cancer at a younger age than white men.

Excess medical expenses, employment disability, and a drop in production at work common in cancer survivors.

Study warns that drug reviewers don't look at long term survival of patients.

Particles protected antigen from premature destruction and prompted the immune system to attack cancer cells.

Kjel Jonhson, PharmD, Vice President of Global Oncology for IMS Health, discusses changes in store for the care of cancer patients over the next decade.

Mass spectrometry reveals all proteins that repair damaged cancer DNA.

Genetically determined telomere length may not influence mortality.

Highest uninsured rates found in patients with testicular, stomach, and cervical cancers.

Taking over-the-counter supplements beyond the recommended amount could increase cancer risk.

Suppression of Wnt signaling pathway shows promise.

Re-engineering antibodies allows them to selectively kill tumors.

Regulating PD-L1 protein that helps cancer evade immune system suggests new therapeutic approach.

Researchers determine mechanism for poor survival rates in African American patients with estrogen-receptor positive breast cancer.

Mild cognitive impairment can set in prior to the start of therapy.

Mortality gap in cancer deaths among African Americans and Caucasians may eventually disappear.

Inhibiting a previously undruggable protein holds promise for treatment of numerous types of cancer.

Longer telomeres gives cancer cells a survival advantage.

Analysis of cancer-causing mutations in the BRCA1 or BRCA2 genes may lead to more effective treatments.